High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes

Leukemia and Lymphoma

Volumn 48, Issue 9, 2007, Pages 1728-1735

  Engelhardt, Brian G ^a   Holland, Derek W ^a   Brandt, Stephen J ^a,b   Chinratanalab, Wichai ^a,b   Goodman, Stacey A ^a,b   Greer, John P ^a   Jagasia, Madan H ^a   Kassim, Adetola A ^a   Morgan, David S ^a   Ruffner, Katherine L ^a,b   Schuening, Friedrich G ^a   Wolff, Steven ^a,c   Bitting, Rhonda ^a   Sulur, Paulgun ^a   Stein, Richard S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Autologous stem cell transplantation; Hodgkin lymphoma; Lymphoid leukemia; Neoplasia

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; MELPHALAN; PREDNISONE; PROCARBAZINE; THIOTEPA; VALACICLOVIR; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONG TERM CARE; LOW DRUG DOSE; LUNG FIBROSIS; LUNG TOXICITY; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIVARIATE ANALYSIS; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34548599996     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701534374     Document Type: Article

References (29)

1. Lasker, S., Gupta, T., Vimal, S., Muckaden, M. A., Saikia, T. K. and Pai, S. K. (2004) Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?. J Clin Oncol, 22, pp. 62-68.
2. Strauss, D. J., Portlock, C. S., Qin, J., Myers, J., Zelenetz, A. D. and Moskowitz, C. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIa nonbulky Hodgkin disease. Blood, 104, pp. 3483-3489.
3. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A. and Wells, W. A. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol, 23, pp. 4634-4642.
4. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R. and Henderson, E. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med, 327, pp. 1478-1484.
5. Duggan, D. B., Petroni, G. R., Johnson, J. L., Glick, J. H., Fisher, R. I. and Connors, J. M. (2003) Randomized comparison of ABVD and MOPP/ABV for the treatment of advanced Hodgkin's disease: Report of an Intergroup Trial. J Clin Oncol, 21, pp. 607-614.
6. Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M. and Brusamolino, E. (1998) A prognostic score for advanced Hodgkin's disease. N Engl J Med, 339, pp. 1506-1514.
7. Sureda, A., Arranz, R., Iriondo, A., Carreras, E., Lahuerta, J. J. and Garcia-Conde, J. (2001) Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol, 19, pp. 1395-1404.
8. Fermé, C., Mounier, N., Divinń, M., Brice, P., Stamatoullas, A. and Reman, O. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Études des Lymphomes de l'Adulte H89 Trial. J Clin Oncol, 20, pp. 467-475.
9. Federico, M., Bellei, M., Brice, P., Brugiatelli, M., Nagler, A. and Gisselbrecht, C. (2003) High-dose therapy and autologus stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol, 21, pp. 2320-2325.
10. Gribben, J. G., Linch, D. C., Singer, C. R., McMillan, A. K., Jarrett, M. and Goldstone, A. H. (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood, 73, pp. 340-344.
11. Kessinger, A., Bierman, P. J., Vose, J. M. and Armitage, J. O. (1991) High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood, 77, pp. 2322-2325.
12. Lavoie, J. C., Connors, J. M., Phillips, G. L., Reece, D. E., Barnett, M. J. and Forrest, D. L. (2005) High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood, 106, pp. 1473-1478.
13. Reece, D. E., Barnett, M. J., Shepherd, J. D., Hogge, D. E., Klasa, R. J. and Nantel, S. H. (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood, 86, pp. 451-456.
14. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M. and Haenel, M. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomized trial. Lancet, 359, pp. 2065-2071.
15. Sweetenham, J. W., Taghipour, G., Milligan, D., Blystad, A. K., Caballero, D. and Fassas, A. (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 20, pp. 745-752.
16. Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., Halpern, J. D. and Horning, S. J. (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89, pp. 814-822.
17. Bierman, P. J., Lynch, J. C., Bociek, R. G., Whalen, V. L., Kessinger, A. and Vose, J. M. (2002) The International Prognostic Factors Project scare for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol, 13, pp. 1370-1377.
18. Brice, P., Bouabdallah, R., Moreau, P., Divine, M., Andre, M. and Aoudjane, M. (1997) Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry. Bone Marrow Transplant, 20, pp. 21-26.
19. Hahn, T., Benekli, M., Wong, C., Moysich, K. B., Hyland, A. and Michalek, A. M. (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant, 35, pp. 557-566.
20. Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Long, G. D. and Hu, W. W. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University Results and Prognostic Indices. Blood, 89, pp. 801-813.
21. Moskowitz, C. H., Nimer, S. D., Zelenetz, A. D., Trippett, T., Hedrick, E. E. and Filippa, D. A. (2000) A 2-step comprehensive high-dose chemoradiotherapy second-line program fro relapsed and refractory Hodgkin's disease: Analysis by intent to treat and development of a prognostic model. Blood, 97, pp. 616-623.
22. Reece, D. E., Connors, J. M., Spinelli, J. J., Barnett, M. J., Fairey, R. N. and Klingemann, H. G. (1994) Intensive Therapy with Cyclophosphamide, Carmustine (BCNU), and Etoposide ± Cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood, 83, pp. 1193-1199.
23. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P. and Young, R. C. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7, pp. 1630-1636.
24. Moritabo, F., Stelitano, C., Luminari, S., Mammi, C., Marcheselli, L. and Callea, V. (2006) The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: A report from the Gruppo Italiano per lo Studio dei Linformi (GISL). Bone Marrow Transplant, 37, pp. 283-288.
25. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
26. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339, pp. 1506-1514.
27. Diehl, V. and Thomas, R. K. (2004) Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol, 5, pp. 19-26.
28. Elkstrand, B. C. and Horning, S. J. (2002) Hodgkin's disease. Blood Rev, 16, pp. 111-117.
29. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J. and Bormans, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, pp. 53-59.